Aquaporin 3 facilitates chemoresistance in gastric cancer cells to cisplatin via autophagy

Cell Death Discovery

Volumn 2, Issue 1, 2016, Pages

  Dong, Xuqiang ^a   Wang, Yao ^a   Zhou, Yangchun ^a   Wen, Jianfei ^a   Wang, Shoulin ^a   Shen, Lizong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85014575638     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2016.87     Document Type: Article

References (31)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.
2. BPharm BA, Jang RW, Wong RK, Swallow CJ, Darling GE, Elimova E. Improving outcomes in resectable gastric cancer: a review of current and future strategies. Oncology (Williston Park) 2016; 30: pii: 217977.
3. Macciò A, Madeddu C. Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity. Expert Opin Pharmacother 2013; 14: 1839–1857.
4. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014; 5: e1257.
5. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869–1883.
6. Lin WM, Li ZG. Blockage of cisplatin-induced autophagy sensitizes cervical cancer cells to cisplatin. Genet Mol Res 2015; 14: 16905–16912.
7. Wang J, Gui Z, Deng L, Sun M, Guo R, Zhang W et al. c-Met upregulates aquaporin 3 expression in human gastric carcinoma cells via the ERK signalling pathway. Cancer Lett 2012; 319: 109–117.
8. Hara-Chikuma M, Satooka H, Watanabe S, Honda T, Miyachi Y, Watanabe T et al. Aquaporin-3-mediated hydrogen peroxide transport is required for NF-kappaB signalling in keratinocytes and development of psoriasis. Nat Commun 2015; 6: 7454.
9. Miller EW, Dickinson BC, Chang CJ. Aquaporin-3 mediates hydrogen peroxide uptake to regulate downstream intracellular signaling. Proc Natl Acad Sci USA 2010; 107: 15681–15686.
10. Papadopoulos MC, Saadoun S. Key roles of aquaporins in tumor biology. Biochim Biophys Acta 2015; 1848: 2576–2583.
11. Shen L, Zhu Z, Huang Y, Shu Y, Sun M, Xu H et al. Expression profile of multiple aquaporins in human gastric carcinoma and its clinical significance. Biomed Pharmacother 2010; 64: 313–318.
12. Chen J, Wang T, Zhou YC, Gao F, Zhang ZH, Xu H et al. Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer. J Exp Clin Cancer Res 2014; 33: 38.
13. Zhou Y, Wang Y, Wen J, Zhao H, Dong X, Zhang Z et al. Aquaporin 3 promotes the stem-like properties of gastric cancer cells via Wnt/GSK-3β/β-catenin pathway. Oncotarget 2016; 7: 16529–16541.
14. Gao L, Gao Y, Li X, Howell P, Kumar R, Su X et al. Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. Mol Oncol 2012; 6: 81–87.
15. Mowers EE, Sharifi MN, Macleod KF. Novel insights into how autophagy regulates tumor cell motility. Autophagy 2016; 12: 1679–1680.
16. Harhaji-Trajkovic L, Arsikin K, Kravic-Stevovic T, Petricevic S, Tovilovic G, Pantovic A et al. Chloroquine-mediated lysosomal dysfunction enhances the anticancer effect of nutrient deprivation. Pharm Res 2012; 29: 2249–2263.
17. Wang J, Feng L, Zhu Z, Zheng M, Wang D, Chen Z et al. Aquaporins as diagnostic and therapeutic targets in cancer: how far we are? J Transl Med 2015; 13: 96.
18. Verkman AS, Hara-Chikuma M, Papadopoulos MC. Aquaporins–new players in cancer biology. J Mol Med (Berl) 2008; 86: 523–529.
19. Kang S, Chae YS, Lee SJ, Kang BW, Kim JG, Kim WW et al. Aquaporin 3 expression predicts survival in patients with HER2-positive early breast cancer. Anticancer Res 2015; 35: 2775–2782.
20. Hou SY, Li YP, Wang JH, Yang SL, Wang Y, Wang Y et al. Aquaporin-3 inhibition reduces the growth of NSCLC cells induced by hypoxia. Cell Physiol Biochem 2016; 38: 129–140.
21. Kang BW, Kim JG, Lee SJ, Chae YS, Jeong JY, Yoon GS et al. Expression of aquaporin-1, aquaporin-3, and aquaporin-5 correlates with nodal metastasis in colon cancer. Oncology 2015; 88: 369–376.
22. Nagaraju GP, Basha R, Rajitha B, Alese OB, Alam A, Pattnaik S et al. Aquaporins: their role in gastrointestinal malignancies. Cancer Lett 2016; 373: 12–18.
23. Ozpolat B, Benbrook DM. Targeting autophagy in cancer management - strategies and developments. Cancer Manag Res 2015; 7: 291–299.
24. Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med 2013; 19: 428–446.
25. Ojha R, Bhattacharyya S, Singh SK. Autophagy in cancer stem cells: a potential link between chemoresistance, recurrence, and metastasis. Biores Open Access 2015; 4: 97–108.
26. Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu Y et al. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des Devel Ther 2015; 9: 6421–6431.
27. Ge J, Chen Z, Huang J, Chen J, Yuan W, Deng Z et al. Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer. PLoS One 2014; 9: e110293.
28. Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH et al. The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett 2015; 360: 195–204.
29. Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009; 625: 220–233.
30. Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC. Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. J Radiat Oncol 2013; 2: 315–321.
31. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 10: 1369–1379.